Beta Bionics, Inc. (BBNX)
| Market Cap | 449.18M |
| Revenue (ttm) | 110.24M |
| Net Income (ttm) | -66.44M |
| Shares Out | 44.56M |
| EPS (ttm) | -1.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,097,733 |
| Open | 10.65 |
| Previous Close | 10.65 |
| Day's Range | 9.95 - 10.88 |
| 52-Week Range | 8.80 - 32.71 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 23.80 (+136.11%) |
| Earnings Date | Apr 21, 2026 |
About BBNX
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which co... [Read more]
Financial Performance
In 2025, Beta Bionics's revenue was $100.25 million, an increase of 53.94% compared to the previous year's $65.12 million. Losses were -$73.20 million, 33.7% more than in 2024.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for BBNX stock is "Strong Buy." The 12-month stock price target is $23.8, which is an increase of 136.11% from the latest price.
News
Beta Bionics to Present at the Bank of America Securities Health Care Conference
IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management ...
Beta Bionics Earnings Call Transcript: Q1 2026
Q1 2026 saw 57% revenue growth to $27.6M, with gross margin expanding to 59.5% and strong pharmacy channel traction. Full-year guidance was raised for revenue, gross margin, and pharmacy mix, while cash reserves remain robust and R&D investments accelerate.
Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial res...
Beta Bionics, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 14, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Beta Bionics, Inc. (“Beta Bionics" or the "Company") (NASDAQ: BBNX) investors that the firm has initiated an investigation ...
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to...
BBNX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options I...
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Continues Investigation of Potential Securities Claims Against Bionics (NASDAQ: BBNX)
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suff...
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suff...
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Beta Bionics
NEW YORK--(BUSINESS WIRE)---- $BBNX #BBNX--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) ...
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suf...
Beta Bionics Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted iLet’s automation, pharmacy reimbursement, and broad patient applicability, with plans to expand the sales force and launch the Mint patch pump by late 2027. The bi-hormonal pump is in phase II trials, and industry trends are validating the company’s business model.
BBNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options ...
Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference
IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management w...
Beta Bionics Earnings Call Transcript: Q4 2025
Delivered 54% year-over-year revenue growth in 2025, driven by strong iLet adoption and pharmacy channel expansion. Guidance for 2026 anticipates continued growth, with increased investment in sales, R&D, and the Mint patch pump, while addressing FDA quality concerns.
Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026
IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial resu...
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suf...
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options I...
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses in Beta Bionics to Contact Him Directly to Discuss Their Options If you suff...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options
BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beta Bionics, Inc...
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Beta Bionics, Inc. (NASDAQ: BBNX)
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Beta Bionics, Inc. (“Beta Bion...
Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to ...
Beta Bionics, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - BBNX
LOS ANGELES, Jan. 15, 2026 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or "the Company") (NASDAQ: BBNX) for...
Beta Bionics Key KPI Miss Targets, Analyst Flags Valuation Risks
Diabetes management solutions provider, Beta Bionics Inc. (NASDAQ: BBNX), on Thursday reported preliminary fourth-quarter 2025 results showing strong revenue growth, driven by rapid expansion in its P...